Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Aptevo Therapeutics ( (APVO) ) has provided an announcement.
On February 3, 2026, Aptevo Therapeutics announced that President and Chief Executive Officer Marvin White, who has led the company since 2016, will retire from the CEO role effective April 1, 2026, becoming Executive Chair while current Chief Operating Officer Jeff Lamothe is promoted to President and CEO and appointed to the board, expanding it from six to seven members. The leadership reshuffle, which also sees current Chairman John E. Niederhuber, M.D., move to Lead Independent Director, is positioned as a continuity-focused transition at what management describes as an inflection point marked by a clinically validated platform, expanded oncology pipeline, and strengthened balance sheet; compensation adjustments, severance-plan changes aligning Executive Chair benefits with CEO-level protections, and Lamothe’s operational and financial track record underscore Aptevo’s intent to maintain strategic momentum and support its next phase of growth in cancer immunotherapies.
The most recent analyst rating on (APVO) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Aptevo Therapeutics stock, see the APVO Stock Forecast page.
Spark’s Take on APVO Stock
According to Spark, TipRanks’ AI Analyst, APVO is a Neutral.
The score is held down primarily by very weak financial performance (no revenue, large ongoing losses, and heavy cash burn) and bearish technical signals (price far below key moving averages with negative MACD). Positive corporate developments—especially the extended funding runway and encouraging trial results—partially offset these risks but are not enough to overcome the current fundamentals and momentum.
To see Spark’s full report on APVO stock, click here.
More about Aptevo Therapeutics
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel multispecific immunotherapies for the treatment of cancer, built on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies. The company’s pipeline includes two clinical candidates—mipletamig for frontline acute myeloid leukemia, which has orphan drug designation, and ALG.APV-527 for multiple solid tumors co-developed with Alligator Bioscience—as well as six preclinical programs targeting a range of solid tumors, reflecting a strategic focus on immune-oncology and differentiated CD3-based therapeutics.
Average Trading Volume: 183,377
Technical Sentiment Signal: Strong Sell
Current Market Cap: $7.25M
See more insights into APVO stock on TipRanks’ Stock Analysis page.